Bioptik Technology (ROCO:4161) Total Equity: NT$974.7 Mil (As of Dec. 2025)


ROCO:4161 Bioptik Technology Inc ROCO:4161
68 GF Score
Price NT$23.00
GF Value NT$27.79
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Bioptik Technology Total Equity?

Bioptik Technology ROCO:4161 68 Total Equity is NT$974.7 Mil as of Dec. 2025. GuruFocus rates ROCO:4161 with a GF Score™ of 68/100 and a GF Value™ of NT$27.79 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Bioptik Technology's total equity for the quarter that ended in Dec. 2025 was NT$974.7 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Bioptik Technology Total Equity Historical Data

* Premium members only.

The historical data trend for Bioptik Technology's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioptik Technology Total Equity Chart

Bioptik Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 694.54 717.83 824.15 905.27 974.69

Bioptik Technology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 905.27 908.24 911.89 947.02 974.69
ROCO:4161
68GF Score
Bioptik Technology Inc ROCO:4161
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioptik Technology Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Bioptik Technology's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1571.836-597.145
=974.7

Bioptik Technology's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1571.836-597.145
=974.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$974.7 Mil mean?
Bioptik Technology (ROCO:4161) has a Total Equity of NT$974.7 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Bioptik Technology and its competitors.
Is Bioptik Technology's Total Equity too high?
Bioptik Technology's current Total Equity is NT$974.7 Mil. Overall, Bioptik Technology has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioptik Technology's Total Equity compare to ABT and SYK?
Bioptik Technology's Total Equity of NT$974.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Bioptik Technology and its competitors. Bioptik Technology's current Total Equity is NT$974.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioptik Technology stock overvalued right now?
Based on GuruFocus' analysis, Bioptik Technology (ROCO:4161) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.79, compared to a current price of NT$23.00 — trading 17.2% below its estimated fair value. The current Total Equity is NT$974.7 Mil. Bioptik Technology's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Bioptik Technology (ROCO:4161), the current Total Equity is NT$974.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioptik Technology (ROCO:4161) Overvalued in 2026?

Based on GuruFocus' analysis, Bioptik Technology stock appears to be undervalued. The current stock price of NT$23.00 is trading 17.2% below its estimated GF Value™ of NT$27.79. GuruFocus considers Bioptik Technology to be Modestly Undervalued.

Key valuation signals for ROCO:4161:

  • Total Equity: NT$974.7 Mil
  • GF Value™: NT$27.79 vs. price of NT$23.00 (17.2% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioptik Technology Business Description

Address No.188, Zhonghua South Road, Miaoli County, Zhunan, TWN, 35057
Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.
68GF Score

Get the complete analysis for ROCO:4161

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$23.00
Price
NT$27.79
GF Value